RA Capital Management: 13F holdings, Q2 2026
Emerging, concentrated · SEC EDGAR filings (CIK 0001346824) · Explore on the interactive board
RA Capital Management disclosed 84 US equity positions worth $11.6bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ASND at 23.7% of the reported book, followed by PARABILIS MEDICINES INC, RYTM. The top ten holdings are 60.0% of the book, and the portfolio behaves like about 13 equal-weight positions. Versus the prior filing it opened 17 new positions, added to 9, reduced 10 and exited 18.
What does RA Capital Management own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 17 new, 9 added, 10 reduced, 18 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | 23.7% | $2.7bn | 10,281,496 | – | new | |
| 2 | PARABILIS MEDICINES INC | 6.8% | $791.9m | 28,933,371 | – | new | |
| 3 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 6.4% | $740.2m | 6,666,837 | 0% | held |
| 4 | PCVX VAXCYTE INC | Healthcare | 5.8% | $667.0m | 11,474,599 | 0% | held |
| 5 | SION SIONNA THERAPEUTICS INC | 3.8% | $435.7m | 9,905,045 | 0% | held | |
| 6 | TYRA TYRA BIOSCIENCES INC | Healthcare | 3.4% | $389.6m | 12,198,625 | 0% | held |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | 2.9% | $341.0m | 8,392,730 | -20% | reduced | |
| 8 | NEWAMSTERDAM PHARMA CO NV | 2.8% | $323.7m | 9,550,191 | 0% | held | |
| 9 | HEMAB THERAPEUTICS HOLDINGS | 2.5% | $286.8m | 7,808,627 | – | new | |
| 10 | SEPN SEPTERNA INC | 2.0% | $234.3m | 6,995,858 | 0% | held | |
| 11 | CLYM CLIMB BIO INC | 2.0% | $230.1m | 11,300,939 | 0% | held | |
| 12 | BCAX BICARA THERAPEUTICS INC | 1.9% | $215.4m | 7,255,993 | 0% | held | |
| 13 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.8% | $207.6m | 7,692,750 | 0% | held |
| 14 | GHRS GH RESEARCH PLC | 1.8% | $205.3m | 7,636,813 | -1% | reduced | |
| 15 | IRON DISC MEDICINE INC | Healthcare | 1.5% | $179.2m | 2,450,221 | 0% | held |
| 16 | SPYGLASS PHARMA INC | 1.5% | $178.6m | 8,021,117 | 0% | held | |
| 17 | ARTV ARTIVA BIOTHERAPEUTICS INC | 1.5% | $174.2m | 17,955,642 | 82% | added | |
| 18 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.5% | $171.9m | 11,189,693 | 0% | held |
| 19 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.4% | $160.4m | 23,555,648 | 0% | held |
| 20 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.4% | $158.3m | 15,827,186 | 0% | held |
| 21 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.4% | $156.7m | 26,975,505 | 0% | held |
| 22 | NUVALENT INC-A | 1.3% | $153.9m | 1,246,456 | -51% | reduced | |
| 23 | ABVX ABIVAX SA-ADR | 1.3% | $150.9m | 1,132,557 | – | new | |
| 24 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.3% | $148.0m | 1,554,597 | – | new |
| 25 | SLDB SOLID BIOSCIENCES INC | Healthcare | 1.0% | $120.2m | 12,036,126 | 29% | added |
| 26 | ZLAB ZAI LAB LTD-ADR | Healthcare | 0.9% | $109.1m | 5,743,533 | 1% | added |
| 27 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.8% | $87.0m | 10,860,977 | 0% | held |
| 28 | XNCR XENCOR INC | Healthcare | 0.7% | $84.9m | 5,274,274 | 8% | added |
| 29 | JBIO JADE BIOSCIENCES INC | 0.7% | $81.6m | 3,671,083 | 0% | held | |
| 30 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.7% | $76.6m | 4,526,926 | – | new |
| 31 | LB PHARMACEUTICALS INC | 0.6% | $71.7m | 2,208,604 | 0% | held | |
| 32 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 0.6% | $70.6m | 1,500,000 | – | new |
| 33 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.6% | $67.3m | 12,723,026 | 87% | added |
| 34 | 4D MOLECULAR THERAPEUTICS IN | 0.6% | $67.2m | 5,049,779 | 0% | held | |
| 35 | SANA SANA BIOTECHNOLOGY INC | Healthcare | 0.6% | $65.4m | 18,750,000 | – | new |
| 36 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 0.5% | $62.4m | 2,399,702 | 0% | held |
| 37 | MNPR MONOPAR THERAPEUTICS INC | 0.5% | $61.8m | 667,207 | 0% | held | |
| 38 | ABOS ACUMEN PHARMACEUTICALS INC | 0.5% | $56.1m | 20,992,669 | 0% | held | |
| 39 | GERN GERON CORP | Healthcare | 0.5% | $54.8m | 42,809,751 | -33% | reduced |
| 40 | RZLT REZOLUTE INC | 0.4% | $49.1m | 9,445,039 | 3% | added | |
| 41 | EVMN EVOMMUNE INC | 0.4% | $46.4m | 3,494,638 | 0% | held | |
| 42 | VOR VOR BIOPHARMA INC | 0.4% | $44.2m | 2,402,095 | -56% | reduced | |
| 43 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.4% | $43.5m | 17,754,430 | 0% | held |
| 44 | AKTS AKTIS ONCOLOGY INC | 0.4% | $42.4m | 1,314,405 | -13% | reduced | |
| 45 | BIOA BIOAGE LABS INC | 0.4% | $41.0m | 1,671,648 | 1% | added | |
| 46 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.3% | $37.4m | 8,000,000 | 0% | held |
| 47 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 0.3% | $37.3m | 318,554 | 0% | held |
| 48 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 0.3% | $36.3m | 1,507,844 | 0% | held |
| 49 | PEPG PEPGEN INC | Healthcare | 0.3% | $36.1m | 20,064,545 | 0% | held |
| 50 | PRLD PRELUDE THERAPEUTICS INC | 0.3% | $34.5m | 6,475,882 | – | new |
What did RA Capital Management sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| ASND ASCENDIS PHARMA A/S - ADR | 75.0% | $2.4bn |
| DNTH DIANTHUS THERAPEUTICS INC | 7.0% | $219.2m |
| PRAX PRAXIS PRECISION MEDICINES I | 3.8% | $120.4m |
| SRPT SAREPTA THERAPEUTICS INC | 2.7% | $84.9m |
| SYRE SPYRE THERAPEUTICS INC | 2.6% | $81.8m |
| FULC FULCRUM THERAPEUTICS INC | 1.5% | $46.4m |
| OLMA OLEMA PHARMACEUTICALS INC | 1.2% | $38.8m |
| DSGN DESIGN THERAPEUTICS INC | 1.0% | $31.6m |
| TVTX TRAVERE THERAPEUTICS INC | 0.7% | $22.2m |
| GRAL GRAIL INC | 0.7% | $22.1m |
| RLMD RELMADA THERAPEUTICS INC | 0.7% | $20.5m |
| STRO SUTRO BIOPHARMA INC | 0.6% | $17.8m |
| CTNM CONTINEUM THERAPEUTICS INC-A | 0.5% | $16.9m |
| INSP INSPIRE MEDICAL SYSTEMS INC | 0.5% | $16.8m |
| HNGE HINGE HEALTH INC-A | 0.4% | $14.1m |
| WGS GENEDX HOLDINGS CORP | 0.4% | $13.5m |
| RNA ATRIUM THERAPEUTICS INC | 0.4% | $11.6m |
| MPLT MAPLIGHT THERAPEUTICS INC | 0.2% | $5.0m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 36.7% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
| Quarter | Positions | Equity value |
|---|---|---|
| Q2 2026 | 85 | $11.6bn |
| Q1 2026 | 86 | $9.5bn |
| Q4 2025 | 72 | $9.8bn |
| Q3 2025 | 68 | $8.2bn |
| Q2 2025 | 64 | $6.0bn |
| Q1 2025 | 86 | $6.0bn |
| Q4 2024 | 90 | $7.6bn |
| Q3 2024 | 82 | $8.8bn |
| Q2 2024 | 79 | $7.7bn |
| Q1 2024 | 76 | $7.9bn |
| Q4 2023 | 62 | $6.4bn |
| Q3 2023 | 66 | $5.1bn |
| Q2 2023 | 54 | $5.3bn |
| Q1 2023 | 59 | $4.4bn |
| Q4 2022 | 70 | $4.9bn |
| Q3 2022 | 81 | $4.7bn |
Earliest filing: Q4 2007 · 73 quarters on file
How concentrated is RA Capital Management's portfolio?
Across every quarter RA Capital Management has filed, its median largest position is 17.9% of the book and its median top-ten weight is 70.5%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 656 completed holding spells, the median lasted 3.0 quarters; 84 positions are still open and their final length is unknown.